Isoantiserum-augmented development of lymphocyte-mediated cytotoxicity.
Passive administration of anti-P-814 isoantiserum (IS) with P-815 mastocytoma was shown to augment the development of T-lymphocyte-mediated cytotoxicity (LMC). The LMC activity augmented by IS was specific to immunizing tumor cells, but required the simultaneous administration of P-815 tumor cells and anti-P-815 serum, suggesting that the antigen-antibody complex is involved in the development of specific cytotoxic T cells. The serum component responsible for augmented development of LMC activity appeared to be IgM in that the augmenting activity fractionated in the void volume of a G-200 Sephadex column and appears very early after immunization. Our experimental results suggest the development of specific T-cell cytotoxicity can be directly regulated by specific IgM antibodies.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D000936:Antigen-Antibody Complex; D003601:Cytotoxicity Tests, Immunologic; D007111:Immunity, Cellular; D007116:Immunization, Passive; D007075:Immunoglobulin M; D007518:Isoantibodies / Q000008:administration & dosage / Q000302:isolation & purification; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D000912:Antibodies, Neoplasm; D000936:Antigen-Antibody Complex; D007075:Immunoglobulin M; D007518:Isoantibodies